*Information based on data from the United States.
Transplantation1More frequent therapy is associated with an increased chance of receiving a transplant.1
Live Longer2More frequent treatments with home haemodialysis have been shown to lower the risk of death.
Less Stress on Your Heart3,4Up to 75 percent of people with chronic kidney disease suffer from a heart complication called left ventricular hypertrophy (LVH).5,6
Time to Recovery7More frequent treatments can improve vitality and give you more energy.
Improved Sexual Function8A small study of 22 men suggests hormone level improvements may help to improve sexual function and patients reported better satisfaction with physical intimacy.
"When I used to look in the mirror there was a guy looking back at me that just he wasn’t there. He was ready to check out. I don’t see that guy any more. For the first time in years I felt good. I started tour guiding again. I’ve started my own tour company now. NxStage gave me my life back."
"It [dialysis] doesn’t interfere in any of our activities. My son recently joined the Navy, and last Mother’s Day he graduated from boot camp and I got to go, which is something I would not have gotten to do if I didn’t have NxStage."
"When I was on in-centre, after each treatment I was tired and I would go home and sleep for hours. My motorcycle just sat in my parent’s garage. I didn’t see my grandkids. When I started more frequent home haemodialysis with System One, I started to feel myself coming back from this dark place. My family recognises me as being back. They see the life in me again."
"In-centre you have no control over your life. They schedule you, hook you up for 4 hours and at the end of the day I would walk out and I didn’t feel well. I even considered taking myself off dialysis because the lifestyle I wanted to live I wasn’t living. When my doctor described home haemodialysis I jumped on it right away."
Risks and Responsibilities
Despite the health benefits that home and more frequent hemodialysis may provide to those with chronic kidney disease, these forms of therapy are not for everyone. Home hemodialysis with the NxStage System One requires a patient and partner who are committed to being trained on and following the guidelines for proper system operation.
The reported benefits of home hemodialysis may not be experienced by all patients.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. When vascular access is exposed to more frequent use, infection of the site, and other access related complications may also be potential risks. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set.
Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep.
Patients should consult their doctor to understand the risks and responsibilities of performing these therapies using the NxStage System.
- Weinhandl E, Liu J, Gilbertson D, Arneson T, Collins A. Transplant incidence in frequent haemodialysis and matched thrice-weekly haemodialysis patients. Poster presented at National Kidney Foundation Spring Clinical Meeting, 2012.
- Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home haemodialysis and matched thrice-weekly in-centre haemodialysis patients. J Am Soc Nephrol. 2012;23(5):895-904.
- FHN Trial Group. In-centre haemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300.
- Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal haemodialysis vs conventional haemodialysis on left ventricular mass and quality of life. JAMA. 2007; 298(11):1291-1299.
- London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving haemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759-2767.
- Cheung AK, Sarnak MJ, Yan GF, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance haemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65(6):2380-2389.
- Jaber BL, Lee Y, Collins AJ, et al. Effect of daily haemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.
- Pinciaroli AR. Results of daily haemodialysis in Catanzaro: 12-year experience with 22 patients treated for more than one year. Hemodial Int. 1998;2(1):12-17.
- Kraus MA, Cox CG, Summitt CL, et al. Work and travel in a large Short Daily haemodialysis (SDHD) program. Abstract presented at American Society of Nephrology Annual Conference, 2007.
- Tennankore K, Nadeau-Fredette AC, Chan CT. Intensified home haemodialysis: clinical benefits, risks and target population. Nephrol Dial Transplant. 2014;29(7):1342-1349.
- Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily haemodialysis improves the long-term health-related quality of life. Kidney Int. 2012;82(5): 561-569.
- Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian haemodialysis. Am J Kidney Dis. 2003;42(1)(suppl 1):S36-S41.
- Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily haemodialysis. Am J Kidney Dis. 2003;42(5):1020-1035.
- Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily haemodialysis. Nephrol Dial Transplant. 2006;21:166-175.